ReviewObesity science & practice2026
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications.
Review in Obesity science & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods: PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA-approved OMMs. We descriptively synthesized lifestyle intervention components including dietary, physical activity, and delivery of counseling. Results: We included 50 reports from 42 studies. Most of the studies included a calorie restriction goal of 500 kcals/day. The most common physical activity goal recommended was ≥ 150 min/week. Diaries for eating and tracking physical activity have been recommended in many studies. There were 22 studies that provided counseling at least monthly or more frequently and an additional 16 trials that provided counseling at least every 3 months. Conclusions: Lifestyle interventions have been core components in Phase 3 trials of FDA-approved OMMs. Further research is needed to test the optimal lifestyle interventions that should be provided along OMMs to maximize health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.